June 13, 2013 - On June 13, 2013 the Supreme Court issued its opinion on the case Association for Molecular Pathology v Myriad Genetics Inc Ruling
The Court ruled that Myriad genetics does not create anything novel when it merely isolates a patients' BRCA1 or BRCA2 gene before analyzing it for mutations related to an elevated risk of breast cancer. Although patent protections for cDNA remained intact in the ruling, many experts felt this would open the doors to researchers and commercial clinical laboratories to test for BRCA1, BRCA2 and other patent-protected genes. This in turn might create a more competitive marketplace for genetic testing and more open, widespread research opportunities for scientists interested in studying both the biology of protected genes and their use and utility in healthcare.
Indeed, in the hours following the Court's announcement, several commercial and academic laboratories announced the pricing and availability of BRCA1 and BRCA2 testing.
Some links to coverage of the ruling are found below:
ScotusBlog: Plain English Version of Ruling
Washington Post coverage
NY Times coverage
NY Times editorial
<< Back to News Releases